Skip to main content
. 2023 Jul 6;20(7):e1004253. doi: 10.1371/journal.pmed.1004253

Table 3. HPV test results.

Intervention group Reference group
Clinician-based sampling Self-sampling Total Total
Age groups (years) Tested women HPV-positive Tested women HPV-positive Tested women HPV-positive HPV16/18% of HPV positive HPV Other % of HPV positive Tested# women HPV-positive HPV16/18% of HPV positive HPV Other% of HPV positive
65–67 1,831 121 (6.6) 763 68 (8.9) 2,594 189 (7.3) 49 (25.9) 140 (74.1) 312 8 (2.6) 3 (37.5) 5 (62.5)
68–69 3,124 173 (5.5) 1,247 93 (7.5) 4,371 266 (6.1) 67 (25.2) 199 (74.8) 431 22 (5.1) 11 (50.0) 11 (50.0)
Total 4,955 294 (5.9) 2,010 161 (8.0) 6,965 455 (6.5) 116 (25.5) 339 (74.5) 743 30 (4.0) 14 (46.7) 16 (53.3)
Screening at age 50–64
Insufficiently screened (≤1 cervical sample) 212 26 (12.3) 231 25 (10.8) 443 51 (11.5) 8 (15.7) 43 (84.3) 65 4 (6.2) 3 (75.0) 1 (25.0)
Sufficiently screened (≥2 cervical samples) 4,743 268 (5.7) 1,779 136 (7.6) 6,522 404 (6.2) 108 (26.9) 296(73.3) 678 26 (3.8) 11 (42.3) 15 (57.7)

Data are provided as number (row percent).

#A combination of cytology and HPV testing with a total of 601 women (81%) who underwent HPV testing.

HPV, human papillomavirus. HPV positive: HPV16 and/or HPV18 and/or 12 other high risk HPV types (HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68).